WASHINGTON DC USA -- PHARMA UPDATE NEWS SERVICE™ -- SEPTEMBER 27, 2012: The Thirteenth Annual Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum (the Pharma Congress), www.PharmaCongress.com, will take place on November 5 - 7, 2012 at the Grand Hyatt in Washington, DC. Registrants may attend the event in person or online (live webcast and archived for 6 months).

FEATURING COMPLIANCE ISSUES IN GLOBAL R&D AND MEDICAL AFFAIRS

Regulatory Enforcement Environment: Has the Bar Moved? Applying Quality Management Principles to R&D Managing Global Trials -- Special Considerations Publication of Clinical Trial Results Support of Medical Education Globally Compliance Challenges with Investigator-Sponsored Research Stuart Horowitz, PhD, MBA President, Institutions & Institutional Services, Arsenal WGH Holdings, Inc., Western Institutional Review Board, Olympia, WA Gerald "Jerry" Kuncio, PhD Deputy Compliance Officer for North America Medical Affairs, GlaxoSmithKline; Former Medical/Scientific Compliance and Ethics Director, AstraZeneca, Philadelphia, PA Ann Meeker-O'Connell, MS, CCEP Office of Policy, Office of the Commissioner, US Food and Drug Administration, Silver Spring, MD Mark Barnes Director of Sponsored Research and Clinical Research Compliance Officer, Harvard University, Cambridge, MA (Co chair) Kathleen Meriwether, Esq. Principal, Fraud Investigation and Dispute Services, Ernst & Young LLP; Philadelphia, PA (Co chair)

KEYNOTE SPEAKERS

Thomas W. Abrams, RPh, MBA Director, Office of Prescription Drug Promotion (OPDP), US Food and Drug Administration, Silver Spring, MD Lanny A. Breuer, Esq. Head, Criminal Division, US Department of Justice, Former Special White House Counsel, Former Assistant District Attorney, New York City, Washington, DC Deirdre Connelly President - North America Pharmaceuticals, GlaxoSmithKline, Former President of US Operations, Eli Lilly and Company, Philadelphia, PA Gregory E. Demske, Esq. Chief Counsel to the Inspector General, Office of Inspector General, Department of Health and Human Services, Washington, DC Susan Dentzer Editor-in-Chief, Health Affairs, Health Policy Analyst, The News Hour with Jim Lehrer, Washington, DC Louis Joseph Freeh, JD, LLM Partner, Pepper Hamilton LLP; Founder and Chairman, Freeh Group International Solutions; Former Director, Federal Bureau of Investigation; Former Judge, United States District Court, Southern District of New York, Wilmington, DE Paul E. Kalb, JD, MD Partner and Global Coordinator, Life Sciences Practice, Sidley Austin LLP, Washington, DC Carmen M. Ortiz, Esq. United States Attorney, District of Massachusetts, Boston, MA Mary E. Riordan, Esq. Senior Counsel, Office of Counsel to the Inspector General, Office of Inspector General, Department of Health and Human Services, Washington, DC

FEATURING PRECONFERENCE SESSIONS Compliance 101 Auditing and Monitoring Boot Camp A Comprehensive Overview of Pharma and Medical Device Corporate Integrity Agreements (CIAs) The New Era of Scrutiny: FCPA Compliance in Pharma Operations PLENARY SESSIONS OIG Update DOJ Criminal Division Update Prosecuting Pharma and Device Fraud FDA-DDMAC Update AUSA Panel Qui Tam Panel State Enforcement Panel Best Practices in Negotiating and Implementing CIAs State Disclosure, Federal Sunshine Act and Global Transparency Life Sciences in America the Morning after the Election Managing Internal and External Investigations PhRMA's New Compliance Work Group Update Global Pharma and Device Compliance Issues and Strategies PHARMA CONGRESS IS

AND MINI SUMMITS Mini Summit I: Co-pay Coupon Litigation Update Mini Summit II: What Enhanced Obligations in CIAs and DPAs say about Agency Expectations for Compliance Programs Mini Summit III: Compliance Issues in Global R&D and Medical Affairs Mini Summit IV: US Disclosure Implementation Update Mini Summit V: Medical Device Compliance Issues Update Mini Summit VI: Global Pharma and Device Compliance Issues Mini Summit VII: Anticorruption, Including FCPA and UK Bribery Act Update Mini Summit VIII: Fair Market Value Update Mini Summit IX: Enforcement Threat Against Individuals Mini Summit X: Global Transparency Update Mini Summit XI: Special Compliance Issues and of Small Pharma and Medical Device Companies Mini Summit XII: Integrating a Culture of Ethics into Your Compliance Program Mini Summit XIII: Government Price Reporting Update Mini Summit XIV: Clinical Trial Disclosure and Results Reporting Liability under FDAAA, Section 801 Mini Summit XV: Board and Management Certifications and Working with an IRO Mini Summit XVI: Drug Samples Disclosure: The Next Horizon? Mini Summit XVII: Professional Responsibilities for Compliance Officers and In-house Counsel in the Pharmaceutical, Biotech and Medical Device Industries Mini Summit XVIII: Compliance Program Innovation

LEADING ASSISTANT US ATTORNEYS

Paul Kaufman, Esq. Assistant US Attorney and Chief, Civil Health Care Fraud, United States Attorney's Office, Eastern District of New York, Brooklyn, NY Marilyn May, Esq. Senior Litigation Counsel, US Attorney's Office, Eastern District of Pennsylvania, United States Department of Justice, Philadelphia, PA Maureen Ruane, Esq. Assistant US Attorney and Chief, Health Care and Government Fraud Unit, Criminal Division, United States, Attorney's Office, District of New Jersey, Newark, NJ Susan Winkler, Esq. Assistant US Attorney, United States Attorney's Office, District of Massachusetts, Boston, MA John T. Bentivoglio, Esq. Partner, Skadden Arps LLP; Former Special Counsel for Healthcare Fraud and Chief Privacy Officer, US Department of Justice, Washington, DC (Moderator)

LEADING STATE PROSECUTORS

Jacob Bergman, Esq. (Invited) Special Assistant Attorney General, Medicaid Fraud Control Unit, NY Office of the Attorney General, New York, NY Keesha Mitchell, Esq. Chief, Health Care Fraud Section, Director, Medicaid Fraud Control Unit, Ohio Attorney General's, Office, Columbus, OH Cynthia O'Keeffe Deputy Chief, Civil Medicaid Fraud Division, Texas Office of the Attorney General, Austin, TX Nicholas N. Paul, Esq. Supervising Deputy Attorney, General, Bureau of Medi-Cal Fraud and Elder Abuse, Office of the Attorney General, California Department of Justice San Diego, CA Virginia "Ginny" A. Gibson, Esq. Partner, Hogan Lovells, US LLP; Former Executive Assistant US Attorney, United States, Attorney's Office, Eastern District of Pennsylvania, Philadelphia, PA (Moderator)

LEADING QUI TAM COUNSEL

Erika A. Kelton, Esq. Partner, Phillips & Cohen LLP, Washington, DC Daniel R. Miller, Esq. Partner, Berger & Montague, PC, Former Deputy Attorney General, Delaware Department of Justice, Philadelphia, PA Michael A. Morse, Esq. Partner, Pietragallo Gordon Alfano Bosick & Raspanti, LLP, Former Assistant District Attorney, Philadelphia District Attorney's Office, Philadelphia, PA Joseph E. B. "Jeb" White, Esq. Partner, Nolan & Auerbach, PA, Philadelphia, PA Kirk Ogrosky, Esq. Partner, Arnold & Porter, Former Deputy Chief, Fraud Section, US Department of Justice, Washington, DC (Moderator)

REPORT FROM THE NEW PhRMA COMPLIANCE WORK GROUP

Kendra Martello, Esq. Assistant General Counsel, PhRMA, Washington, DC Anne Nobles, MA, JD Chief Ethics and Compliance Officer and Senior Vice President Enterprise Risk Management, Eli Lilly and Company, Indianapolis, IN

COMPLIANCE 101

Gary DelVecchio Executive Director, US Pharmaceutical Compliance and Ethics, Bristol-Myers Squibb Company, Plainsboro, NJ Margaret K. Feltz, Esq. Director, Corporate Compliance, Purdue Pharma LP, Stamford, CT Michael Kendall, Esq. Partner and Head, White-Collar Defense Group, McDermott Will & Emery LLP, Former Deputy Associate Attorney General and Counselor, United States Department of Justice, Boston, MA Janet L. "Lucy" Rose Founder, Lucy Rose and Associates, Former Director, Division of Drug Marketing, Advertising, and Communications (DDMAC), FDA, Washington, DC Kelly B. Freeman, PhD Ethics and Compliance Officer, Eli Lilly and Company, Indianapolis, IN (Moderator)

DRUG SAMPLES DISCLOSURE: THE NEXT HORIZON?

Kendra Martello, Esq. Assistant General Counsel, PhRMA, Washington, DC Marilyn May, Esq. Senior Litigation Counsel, US Attorney's Office, Eastern District of Pennsylvania, United States Department of Justice, Philadelphia, PA Kate Whelley McCabe, Esq. (Invited) Assistant Attorney General, Public Protection Division, Vermont Office of the Attorney General, Montpelier, VT Karen Rothschild, Esq. (Invited) Regulatory Counsel, Office of Compliance, Center for Drug Evaluation and Research, Food and Drug Administration, Washington, DC John Patrick Oroho, Esq. Executive Vice President and Chief Strategy Officer, Porzio Pharmaceutical Services, LLC, Principal, Porzio, Bromberg & Newman PC, Morristown, NJ (Moderator)

INTEGRATING A CULTURE OF ETHICS INTO YOUR COMPLIANCE PROGRAM

Paul J. McNulty, Esq. Partner and Chairs, Global Corporate Compliance Steering Committee, Baker & McKenzie LLP, Former Deputy Attorney General, US department of Justice, Washington, DC Matthew Pachman, Esq. Vice President and Chief Ethics Officers, FTI Consulting, VP, Chief Compliance Officer, Altegrity, VP, Compliance, Ethics and Business Practices, Freddie Mac, Director, Legal (and Ethics), MCI, Washington, DC Jeffrey S. Paden Deputy Compliance Officer, GlaxoSmithKline, Research Triangle Park, NC Caroline West, Esq. Senior Vice President, Chief Compliance and Risk Officer, Shire Pharmaceuticals, Inc., Philadelphia, PA (Moderator)

ANTICORRUPTION UPDATE

Gary F. Giampetruzzi, Esq. Vice President and Assistant General Counsel, Head of Government Investigations, Pfizer Inc., New York, NY Michael Kendall, Esq. Partner and Head, White-Collar Defense Group, McDermott Will & Emery LLP, Former Deputy Associate Attorney General and Counselor, United States Department of Justice, Boston, MA Vivian Robinson, Esq. Partner, McGuireWoods, Former General Counsel of the UK Serious Fraud Office Former Head, QEB Hollis Whiteman Chambers, Recorder of the Crown Court and Treasurer of Inner Temple, London, UK

THE NEW ERA OF SCRUTINY: FCPA COMPLIANCE IN PHARMA OPERATIONS

Gregory A. Paw, Esq. Partner, Pepper Hamilton LLP, Former Director, Division of Criminal Justice, Office of the New Jersey Attorney General, Former Deputy US Attorney, US Attorney's Office for the Eastern District of Pennsylvania, Philadelphia, PA John G. Rahie, JD, LLM Partner, Freeh Sporkin & Sullivan, LLP, Former Executive Director of Global Investigations, General Motors Corporation, Washington, DC

ENFORCEMENT THREAT AGAINST INDIVIDUALS

Thomas M. Gallagher, Esq. Chair, White Collar Litigation and Investigations Practice Group, Pepper Hamilton LLP, Philadelphia, PA Lori Queisser Principal, Advisory Services, KPMG LLP, Former Senior Vice President, Global Compliance, and Business Practices, Schering-Plough Corporation, Former Member, PCF Executive Committee, Indianapolis, IN

BEST PRACTICES IN NEGOTIATING AND IMPLEMENTING A CIA

Cynthia Cetani Vice President, Ethics & Compliance, Chief Compliance Officer, Novartis Pharmaceuticals Corporation, New York, NY Lauran S. D'Alessio Vice President and Compliance Officer, Merck & Co., Whitehouse Station, NJ Kris Curry Vice President, Health Care Compliance, Johnson & Johnson Pharmaceuticals, Titusville, NJ Michael L. Shaw Vice President & Compliance Officer, GlaxoSmithKline-North America Pharmaceuticals, Former Senior Counsel, Office of Inspector General, Philadelphia, PA Thomas A. Gregory, CFA, MBA Partner, Fraud Investigation & Dispute Services, Ernst & Young LLP, Atlanta, GA (Moderator)

A COMPREHENSIVE OVERVIEW OF PHARMA AND MEDICAL DEVICE CORPORATE INTEGRITY AGREEMENTS (CIAS)

Tracy Mastro, MBA Senior Director, Life Sciences Advisory Services, Huron Consulting Group, Washington, DC Paige Slater, PA-C Global CIA Program Director, Corporate Ethics and Compliance, Synthes, Inc., West Chester, PA Bert Weinstein, Esq. Vice President, Corporate Compliance, Purdue Pharma LLP; Former Member, PCF Executive Committee, Stamford, CT Wendy C. Goldstein, Esq. Partner, Epstein Becker & Green, New York, NY (Moderator) Paul J. Silver Practice Leader, Life Sciences Advisory Services, Huron Consulting Group, Atlanta, GA (Moderator)

WHAT ENHANCED OBLIGATIONS IN CIAs AND DPAs SAY ABOUT AGENCY EXPECTATIONS FOR COMPLIANCE PROGRAMS

Steve Guymon US Medical Compliance Officer, Eli Lilly and Company, Indianapolis, IN Steven J. Tave, Esq. Counsel, Gibson, Dunn & Crutcher LLP; Former Associate Chief Counsel for Enforcement, Office of Chief Counsel, US Food and Drug Administration, Washington, DC Thomas W. Beimers, Esq. Special Counsel, Faegre Baker Daniels; Former Senior Counsel for Administrative and Civil Remedies, Office of the Inspector General, US Department of Health and Human Services, Minneapolis, MN (Moderator) Edward Nowicki, Esq. Vice President and Assistant General Counsel, Pfizer Inc., New York, NY (Moderator)

BOARD AND MANAGEMENT CERTIFICATIONS AND WORKING WITH AN IRO

Victoria Browning Senior Director Corporate Compliance Operations, Allergan Inc., Irvine, CA Daniel J. Garen, Esq. Senior Vice President and Chief Compliance Officer, Wright Medical Technology, Inc., Former Chief Compliance Officer and Senior Counsel, Siemens Healthcare Sector, Arlington, TN Meredith Manning, Esq. Co-director, Pharmaceutical and Biotechnology, Practice Group, Hogan Lovells LLP, Former Assistant US Attorney, Civil Division, US Attorney's Office in Washington, DC, Former Associate Chief Counsel, Office of General Counsel, FDA, Washington, DC Jean McKiernan Director, Advisory Pharmaceutical and Life Sciences, PwC Chicago, IL

STATE DISCLOSURE LAWS, SUNSHINE ACT AND GLOBAL TRANSPARENCY INITIATIVES

Niall Brennan, MPP (Invited) Acting Director, Policy and Data Analysis Group, Centers for Medicare and Medicaid Services, Washington, DC William E. Buzzeo, MS Vice President and General Manager, Compliance Solutions Division, Cegedim Relationship Management, Richmond, VA Katrina S. Cahill Senior Manager, Global Transparency Lead, Biogen Idec, Weston, MA Trudy J. Seeley Senior Manager, Transparency Operations, Sanofi US, Bridgewater, NJ Jonathon Kellerman Principal, Pharmaceutical and Life Sciences, Advisory Services, PwC, Florham Park, NJ (Moderator)

US DISCLOSURE IMPLEMENTATION UPDATE

Daniel Char, Esq. Associate General Counsel - Commercial, Smith & Nephew, Boston, MA Diane Cruz-Burke, Esq. Assistant General Counsel, Eli Lilly and Company, Indianapolis, IN Gus Papandrikos, MBA Director Transparency Operations, Sanofi, New York, NY Eve M. Brunts, JD, LLM Partner, Ropes & Gray, Boston, MA (Moderator) Jack T. Tanselle Director, Healthcare Dispute, Compliance and Investigation Practice, Navigant Consulting, Inc., Indianapolis, IN (Moderator)

GLOBAL TRANSPARENCY UPDATE

Peter Burberry Senior Director, Global Practices, Business Practice Management, Allergan Inc., Irvine, CA Michael O'Connor, MS Executive Director, IS Business Consulting, Boehringer Ingelheim, New York, NY Katrina S. Cahill Senior Manager, Corporate Compliance - Global Transparency Lead, Biogen Idec, Weston, MA William E. Buzzeo, MS Vice President and General Manager, Compliance Solutions Division, Cegedim Relationship Management, Richmond, VA (Moderator) Kelly N. "Nikki" Reeves, MPA, JD Partner, King & Spalding LLP, Washington, DC (Moderator)

PROFESSIONAL RESPONSIBILITY FOR PHARMA, DEVICE AND BIOTECH IN-HOUSE COUNSEL AND COMPLIANCE PROFESSIONALS

Edward (Ed) Berg, Esq. Vice President, Associate General Counsel, Sanofi, New York, NY Robert Hoehn, Esq. Health Care Compliance Officer, Acclarent (a Johnson & Johnson company), San Francisco, CA Freddy Jimenez, Esq. Assistant General Counsel, Johnson & Johnson, New Brunswick, NJ Jeffrey Klimaski, CPA Vice President, Corporate Ethics & Compliance Officer, BTG International Inc., Philadelphia, PA Thomas E. Costa Vice President, US Pharmaceuticals Compliance, Bristol-Myers Squibb Co., Princeton, NJ Christopher D. Zalesky, JD, CCEP, RAC Vice President Global Policy and Guidance, Johnson & Johnson Health Care Compliance and Privacy, New Brunswick, NJ (Moderator)

AUDITING AND MONITORING BOOT CAMP

Lori Alarimo, Esq. Vice President and Deputy Compliance Officer, Allergan, Former Assistant General Counsel, Pfizer, Irvine, CA Thomas C. Frongillo, Esq. Partner, Head of Litigation (Boston Office) and Co-Chair, White Collar Criminal Practice, Weil Gotshal & Manges, Boston, MA Jeffrey L. Handwerker, Esq. Partner, Arnold & Porter LLP, Washington, DC Michael Hercz, Esq. Director, Audit and Enterprise Risk Services, Deloitte & Touche LLP; Former Vice President and Chief Compliance Officer, Victory Pharmaceuticals, Inc., Costa Mesa, CA Vickie L. McCormick Vice President, Health Care Compliance, DePuy, Inc.; Chief Compliance Officer, DePuy Orthopaedics, Inc.; Former Chief Compliance Officer, St. Jude Medical, Warsaw, IN Jeff Rosenbaum Vice President, Chief Compliance Officer, Vertex Pharmaceuticals; Former Global Head, Ethics & Compliance, Novartis Oncology, Boston, MA L. Stephan Vincze, JD, LL M, MBA Director, Audit and Enterprise, Risk Services, Deloitte & Touche LLP; Former Vice President, Ethics and Compliance Officer/Privacy Officer, TAP Pharmaceutical Products Inc., Boston, MA (Moderator)

GOVERNMENT PRICE REPORTING UPDATE

George Kenny, Esq. Senior Account Manager, 340B, Genentech, San Francisco, CA Cambria Smith, Esq. Senior Corporate Counsel, Healthcare Law Group, Genentech, Former Senior Counsel, Amgen, San Francisco, CA Marcy Imada Principal, Deloitte & Touche LLP, Los Angeles, CA (Moderator) John D. Shakow, Esq. Partner, FDA & Life Sciences Practice, King & Spalding, Washington, DC (Moderator)

CO-PAY COUPON LITIGATION UPDATE

Perry Goldman, Esq. Vice President and Deputy General Counsel, Onyx Pharmaceuticals, San Francisco, CA William A. Sarraille, Esq. Partner, Sidley Austin LLP, Washington, DC Richard L. Zimmerer Partner, Forensic Advisory Services, KPMG LLP, Los Angeles, CA

COMPLIANCE EFFECTIVNESS REVIEWS: BENEFITS TO THE BOARD OF DIRECTORS AND BEYOND

Joseph Cacciatore, MBA Executive Director, Ethics & Compliance, Novartis Pharmaceuticals Corporation, East Hanover, NJ Saul B. Helman, MD, MBA Managing Director, Disputes and Investigations Practice, Navigant, Chicago, IL

FAIR MARKET VALUE UPDATE

Mark A. DeWyngaert, PhD Managing Director, Huron Consulting Group, LLC, New York, NY Fred Eaton, MBA Partner, Polaris Management Partners, New York, NY Prateep Menon, CFA Principal, Deloitte Financial Advisory Services LLP, New York, NY John Moose, MBA, CPA, ABV Manager, Huron LifeSciences, Chicago, IL

COMPLIANCE ISSUES IN GLOBAL R&D AND MEDICAL AFFAIRS

Stuart Horowitz, PhD, MBA President, Institutions & Institutional Services, Arsenal WGH Holdings, Inc., Western Institutional Review Board, Olympia, WA Gerald "Jerry" Kuncio, PhD Deputy Compliance Officer for North America Medical Affairs, GlaxoSmithKline; Former Medical/Scientific Compliance and Ethics Director, AstraZeneca, Philadelphia, PA Mark Barnes Director of Sponsored Research and Clinical Research Compliance Officer, Harvard University, Cambridge, MA (Moderator) Kathleen Meriwether, Esq. Principal, Fraud Investigation and Dispute Services, Ernst & Young LLP; Philadelphia, PA (Moderator)

CLINICAL TRIAL DISCLOSURE AND RESULTS REPORTING LIABILITY UNDER FDAAA, SECTION 801

Jeffrey K. Francer, MPP, JD Assistant General Counsel, PhRMA; Former Associate Chief Counsel, US Food and Drug Administration, Washington, DC, USA Ann Meeker-O'Connell, MS, CCEP Office of Policy, Office of the Commissioner, US Food and Drug Administration, Silver Spring, MD Marc B. Wilenzick, Esq. Compliance Officer/Chief Compliance Counsel, R&D and Medical, Pfizer Inc., New York, NY Julie Finegan, Esq. Associate Chief Counsel, US Food and Drug Administration, Silver Spring, MD (Moderator)

SPECIAL COMPLIANCE ISSUES AND STRATEGIES OF SMALL PHARMACEUTICAL AND MEDICAL DEVICE COMPANIES

Justin A. Dillon Vice President, Chief Ethics and Compliance Officer, Ipsen Biopharmaceuticals, Inc.; Former Deputy Ethics and Compliance Officer, North America Pharma and Vaccines, GlaxoSmithKline, Basking Ridge, NJ Jeffrey Klimaski, MBA, CPA Vice President, Corporate Ethics and Compliance Officer, BTG International Inc.; Former Vice President, Global Ethics and Compliance Officer, Stiefel Laboratories, Inc., West Conshohocken, PA Daniel A. Kracov, Esq. Partner and Head, FDA and Healthcare Practice, Arnold & Porter, Washington, DC Timothy Ayers, JD, MPH Vice President and Chief Compliance Officer, Dendreon; Former Associate General Counsel and Executive Director of Compliance, Seattle Genetics, Bothell, WA (Moderator) Elizabeth V. Jobes, Esq. Senior Vice President and Chief Compliance Officer, Auxilium Pharmaceuticals Inc; Former Vice President and Chief Compliance Officer, Adolor, Philadelphia, PA (Moderator)

MEDICAL DEVICE COMPLIANCE ISSUES UPDATE

Eileen Erdos Principal, Fraud Investigation and Dispute Services, Ernst & Young LLP, Chicago, IL, USA J. J. Kuhn, Esq. Senior Director, Ethics and Compliance, Medtronic Neuromodulation, Minneapolis, MN Sujata T. Dayal, Esq. Corporate Vice President and Chief Compliance Officer, Biomet, Former Counsel, Domestic, Legal Operations, Abbott Laboratories, Former Member, PCF Executive Committee, Warsaw, IN (Moderator) Ronald L. Wisor, Jr., Esq. Partner, Hogan Lovells US LLP, Washington, DC (Moderator)

GLOBAL PHARMA AND DEVICE COMPLIANCE ISSUES AND STRATEGIES

Sue Egan Director and Principal Consultant, Sue Egan Associates, Editor, Life Science Compliance, Former Vice President Compliance, AstraZeneca, Great Missenden, Buckinghamshire, UK Keith M. Korenchuk, JD, MPH Partner, Arnold & Porter LLP, Washington, DC Abdul Luheshi, MBA, PhD Vice President Health Care Compliance, Asia Pacific, Johnson & Johnson International, Inc., Co-chair, Asia Pacific American Pharma Congress, Singapore Clivetty Martinez, PhD Regional Vice President Latin America, Office of Healthcare Compliance and Privacy, Johnson & Johnson International, Inc., Chair, Latin American Ethics and Compliance Network, Co-chair, Latin American Pharma Congress, Miami, FL Vincenzo Salvatore, Esq. Senior Counsel, Sidley Austin LLP, Professor of International Law, University of Insubria, Former Head of Legal Service, European Medicines Agency, Varese, Italy Yuet-Ming Tham, Esq. Partner, Sidley Austin LLP, Hong Kong Roeland Van Aelst Vice President EMEA & Canada, Office of Health Care Compliance & Privacy, Johnson & Johnson International, Inc., Board Member, International Society of Healthcare, Ethics and Compliance Professionals (ethics), Co-chair, Latin American Pharma Congress, Brussels, Belgium Michael K. Volz, LLM Group Compliance Officer, Merck KgaA, Frankfurt Am Main, Germany Brian Riewerts Partner, Global Pharmaceuticals and Life Sciences, PwC, Baltimore, MD (Moderator)

The Pharmaceutical Compliance Forum (PCF) is a coalition of senior compliance professionals and legal counsel from more than 50 of the largest research-based pharmaceutical manufacturers. The PCF was founded in early-1999 by compliance professionals from the pharmaceutical industry to promote effective corporate compliance programs. The members meet twice a year, for two days, focusing on open and informal sharing of compliance information, best practices, and current developments in the field, and sponsors a two-day international compliance congress in the Spring and a three-day US compliance congress each Fall.

This site complies with the HONcode standard for trustworthy health information:
verify here.